Table 1. MiHAs detected by MS in only one of the two subjects and resulting from ns-SNPs in MIP-coding regions.
| MiHA name | Detected MiHA sequence | S | Gene symbol | HLA allele | IC50 (nM) | aa sub.1 | aa sub.2 | Alternative MiHA variant | IC50 (nM) | IC50 ratio | dbSNP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) | |||||||||||
| ITGAL-1T* | STALRLTAF | 1 | ITGAL | C*16:01 | 306 | TR | RR | SRALRLTAF | 2,969 | 9.7 | rs2230433 |
| IGHV5-51-1V | VIYPGDSDTRY | 1 | IGHV5-51 | A*29:02 | 27 | VI | SS | I/SIYPGDSDTRY | 19/31 | 0.7/1.1 | rs199610746 |
| NQO1-1R* | AMYDKGPFRSK | 2 | NQO1 | A*03:01 | 12 | WW | RW | AMYDKGPFWSK | 11 | 0.9 | rs1131341 |
| GRP-1R | RELPLVLL | 2 | GRP | B*44:03 | 285 | SS | RR | SELPLVLL | 159 | 0.6 | rs1062557 |
| C13orf18-1R* | RVSLPTSPR | 2 | C13orf18 | A*03:01 | 235 | GG | RR | RVSLPTSPG | 11,858 | 50.5 | rs1408184 |
| IGLV2-11-1HH* | SDVGGHHY | 2 | IGLV2-11 | A*29:02 | 660 | YY-NN | HH-HH | SDVGGYNY | 412 | 0.6 | — |
| (B) | |||||||||||
| R3HCC1-1H | AENDFVHRI | 1 | R3HCC1 | B*44:03 | 61 | HH | HR | AENDFVRRI | 123 | 2 | rs11546682 |
| NADK-1K | AVHNGLGEK | 2 | NADK | A*03:01 | 229 | KN | KK | AVHNGLGEN | 24,349 | 106.3 | rs4751 |
| ACC-2G | KEFEDGIINW | 2 | BCL2A1 | B*44:03 | 49 | GD | GG | KEFEDDIINW | 59 | 1.2 | rs3826007 |
| KIF20B-1I | QELETSIKKI | 2 | KIF20B | B*44:03 | 288 | IN | II | QELETSNKKI | 615 | 2.1 | rs12572012 |
HLA, human leukocute antigen.
All MiHAs have one single genetic origin and are coded by an unshared (A) or shared allele (B) between subjects. Selected features of the MiHAs are shown: the detected amino-acid sequence (polymorphic residues are highlighted in bold underlined), the subject (S) in which the MiHA was detected, the source gene, the HLA molecule for which the MiHA has the best predicted binding affinity (IC50), the translated genotype of the polymorphic loci shown in amino acids (aa) for each subject, the alternative MiHA variant and its predicted HLA-binding affinity (IC50), the differential predicted HLA-binding affinity of the variant relative to the detected peptide (IC50 ratio) and the dbSNP identification when the ns-SNP corresponds to a known SNP. IC50 values of the alternative MiHA variants and IC50 ratios are shown in italics when they show a fold difference ≥2 relative to the detected MiHAs. Further features can be found in Supplementary Data 3.
*MiHAs tested in cytotoxicity assays (see Fig. 5a).